Feature Q&A with Jo Watson

This event was held Thursday 7 October 2021.

Jo Watson, the Consumer Rep of the Pharmaceutical Benefits Advisory Committee (PBAC) was our guest. This event allowed responses to questions regarding the recent non-recommendation of Evrysdi (Risdiplam) that were submitted to SMA Australia ahead of the event.

Jo explained the importance of completing the PBAC consumer comments for the upcoming PBAC meeting that will be considering Spinraza (Nusinursen) for adults.

Feature Q and A with Jo Watson

Subscribe to our Newsletter